Telix Pharmaceuticals Ltd
corporate_fare Company Profile
Telix Pharmaceuticals Ltd (NASDAQ:TLX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 34 items for TLX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for TLX spans 6-K, 4.
Recent high-impact activity:
- Telix Sets Dec 1 Vote on ITM Deal; Up to 114.2M Shares, 25.1% Seller Stake
- Telix Q3 Revenue US$245M (+19%); Narrows FY26 R&D Guidance, Confirms >US$1B FY26
- Telix Q3 Revenue Up 19% to $245M, Reaffirms $1B+ Full-Year Outlook
- FDA Grants Fast Track Designation to Telix's BiPASS Prostate Imaging Program
- Telix to Acquire ITM for US$1.65B, Creating a Radiopharmaceutical Powerhouse
Financial Snapshot
Short Interest & Short Volume
1.10 days to coverFINRA reported short interest of 352,936 shares in TLX as of the October 15, 2026 settlement, a 17.3% decrease from the prior period — about 1.1 days to cover at its recent average daily volume. On October 30, 2026, 37.7% of TLX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for TLX, detected from its recent SEC filings · based on capital-structure filings through 2026-08-20.
ATM Facility Established · Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
TLX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.